All In Biotech

NDA 020708 · Abbvie Endocrine INC

Lupron Depot

Leuprolide Acetate · Injection

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Mar 7, 1997

Approved uses

3

Original approval plus efficacy supplements

Registered trials

457

123 Phase 3, 53 recruiting

FAERS reports

29,123

17,188 serious, 4,144 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 10, 2025.

LUPRON DEPOT 11.25 mg is a gonadotropin-releasing hormone (GnRH) agonist indicated for: Endometriosis Management of endometriosis, including pain relief and reduction of endometriotic lesions. ( 1.1 ) In combination with a norethindrone acetate for initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms. ( 1.1 ) Limitations of Use: The total duration of therapy with LUPRON DEPOT 11.25 mg plus add-back therapy should not exceed 12 months due to concerns about adverse impact on bone mineral density. ( 1.1 , 2.1 , 5.1 ) Uterine Leiomyomata (Fibroids) Concomitant use with iron therapy for preoperative hematologic improvement of women with anemia caused by fibroids for whom three months of hormonal suppression is deemed necessary. ( 1.2 ) Limitations of Use: LUPRON DEPOT 11.25 mg is not indicated for combination use with norethindrone acetate add-back therapy for the preoperative hematologic improvement of women with anemia caused by heavy menstrual bleeding due to fibroids. ( 1.2 ) 1.1 Endometriosis Monotherapy LUPRON DEPOT 11.25 mg is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. In Combination with Norethindrone Acetate LUPRON DEPOT 11.25 mg in combination with norethindrone acetate is indicated for initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms. Use of norethindrone acetate in combination with LUPRON DEPOT 11.25 mg is referred to as add-back therapy, and is intended to reduce the loss of bone mineral density (BMD) and reduce vasomotor symptoms associated with use of LUPRON DEPOT 11.25 mg. Limitations of Use : The total duration of therapy with LUPRON DEPOT 11.25 mg plus add-back therapy should not exceed 12...

Mechanism: Leuprolide acetate is a long-acting GnRH analog. A single injection of LUPRON DEPOT 11.25 mg results in an initial stimulation followed by a prolonged suppression of pituitary gonadotropins. Repeated dosing of LUPRON DEPOT 11.25 mg at quarterly intervals results in decreased secretion of gonadal steroids. Consequently, tissues and functions that depend on gonadal steroids for their maintenance become quiescent. This effect is reversible on discontinuation of drug therapy. Leuprolide acetate is not active when given orally.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LUPRON DEPOT · LEUPROLIDE ACETATE 11.25MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Leuprolide" as an intervention, any sponsor and status, largest first.

All 457 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hot flush3,487
  • death2,333
  • fatigue1,923
  • headache1,462
  • pain1,285
  • drug ineffective1,187
  • nausea1,180
  • arthralgia1,082
  • asthenia998
  • abdominal pain942
  • off label use938
  • vaginal haemorrhage878

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004127
2005119
2006106
2007141
2008506
2009978
20101,324
20111,582
20121,181
20131,670
20142,641
20152,663
20161,865
20171,342
20181,384
20191,495
20201,350
20211,527
20221,854
20231,614
20241,500
20251,148
20261,006

Recalls

1 FDA enforcement reports for this application.

  • Mar 10, 2014 · Class II · Terminated

    Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lupron Depot (Leuprolide Acetate)

2024 spending

$164M

Beneficiaries

11,482

31,645 claims

Per beneficiary

$14,283

$5,177.85 per unit

View as table
YearSpending
2020$82,608,206
2021$82,903,168
2022$107,502,481
2023$128,884,249
2024$163,997,487

Part B: Lupron Depot* (Leuprolide Acetate*) · HCPCS J1950

2024 spending

$11.2M

Beneficiaries

1,111

4,163 claims

Per beneficiary

$10,111

2024 ASP limit $1,608.08 per unit

View as table
YearSpending
2020$6,502,353
2021$6,456,999
2022$8,232,155
2023$10,345,855
2024$11,233,617

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 569 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.